Telomir Pharmaceuticals: enters private placement for approximately $5,600,000

What happened The filing says that on Oct 5, 2026, Telomir Pharmaceuticals, Inc. entered into a securities purchase agreement and agreed to issue and sell 4,843,300 shares of common stock in a private placement. The filing says the purchase price was $1.16 per share, representing a 5% discount to the applicable 10-day volume-weighted average price ending two days prior to the closing, and that the gross proceeds were approximately $5,600,000. The filing says that John Paul DeJoria invested an additional $1,000,000 and that the closing occurred on Oct 5, 2026. The filing says the company also entered into a registration rights agreement requiring it to file a registration statement within 30 days of the closing.

Key details

• 4,843,300 shares sold at $1.16 per share; gross proceeds approximately $5,600,000.
• Closing date Oct 5, 2026; investor John Paul DeJoria contributed $1,000,000.
• Alexander Capital acted as placement agent and is entitled to a cash fee of 9.0% of gross proceeds (approximately $455,000) plus reimbursement of documented expenses up to $40,000.
• Placement agent received warrants to purchase 387,464 shares (8.0% of shares sold) at $1.16 per share, exercisable for cash and expiring five years after issuance.

Why it may matter The filing reports Item 1.01 (entry into a material definitive agreement) describing the securities purchase agreement and related registration rights, Item 3.02 (unregistered sales of equity securities) describing the private placement, and Item 7.01 (regulation FD disclosure) reporting a press release. This filing does not show why the insider traded or why the company acted.